Clinical Trials
1,905 trialsAn Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer Pain
Janssen-Cilag Ltd.
A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies
Constellation Pharmaceuticals
PROACC-1
Pfizer
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Sanofi
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
POM MM 014
Celgene
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Servier
Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients
Trishula Therapeutics, Inc.
PM14 Administered Intravenously to Patients With Advanced Solid Tumors
PharmaMar
Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer
Xcovery Holdings, Inc.
NeoRay
Advanced Accelerator Applications
NAVIGATE
Bayer
Evaluation of Safety and Efficacy of Three Flavors of SupportanĀ® Drink in Cancer Patients in Taiwan
Fresenius Kabi Taiwan Ltd.
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors
Seqker Biosciences, Inc.
COMBI-AD
Novartis
AURA
AstraZeneca
BOOST
Benfovir AG
ENGOT-EN5
Karyopharm Therapeutics Inc
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients
NaviFUS Corporation
VIOLETTE
Koelis
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Tasly Pharmaceutical Group Co., Ltd
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders
Celgene
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
Boehringer Ingelheim
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
TirbAKare
Almirall, S.A.
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
TRANSFORM-1
AbbVie
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
OPTIC
Takeda
MK-4700-001
Merck Sharp & Dohme LLC
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Varian ProBeam Proton Therapy System Clinical Trial (Shandong)
Varian, a Siemens Healthineers Company
FALCON
AstraZeneca
COLUMBUS
Pfizer
CaRe
Inmune Bio, Inc.
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
Using an Artificial Intelligence Medical Device to Help Primary Care Practitioners Identify and Manage Skin Conditions (Tumor, Inflammatory, and Infectious Diseases) in Adult Patients at Pozuelo and Majadahonda Health Centers
AI Labs Group S.L
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
REALNESS
AstraZeneca
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors
Janssen Research & Development, LLC
MAGE-A10į¶ā·ā¹ā¶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
Adaptimmune